In the latest trading session, 0.52 million Precision Biosciences Inc (NASDAQ:DTIL) shares changed hands as the company’s beta touched 1.41. With the company’s most recent per share price at $5.37 changed hands at -$0.33 or -5.86% at last look, the market valuation stands at $42.34M. DTIL’s current price is a discount, trading about -261.82% off its 52-week high of $19.43. The share price had its 52-week low at $3.61, which suggests the last value was 32.77% up since then. When we look at Precision Biosciences Inc’s average trading volume, we note the 10-day average is 2.13 million shares, with the 3-month average coming to 437.53K.
Analysts gave the Precision Biosciences Inc (DTIL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended DTIL as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Precision Biosciences Inc’s EPS for the current quarter is expected to be -2.94.
Precision Biosciences Inc (NASDAQ:DTIL) trade information
Instantly DTIL was in red as seen in intraday trades today. With action 12.96%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 40.83%, with the 5-day performance at 12.96% in the green. However, in the 30-day time frame, Precision Biosciences Inc (NASDAQ:DTIL) is -6.68% down. Looking at the short shares, we see there were 0.27 million shares sold at short interest cover period of 2.78 days.
The consensus price target for the stock as assigned by Wall Street analysts is 15.5, meaning bulls need an upside of 65.35% from its recent market value. According to analyst projections, DTIL’s forecast low is 1 with 30 as the target high. To hit the forecast high, the stock’s price needs a -458.66% plunge from its current level, while the stock would need to tank 81.38% for it to hit the projected low.
Precision Biosciences Inc (DTIL) estimates and forecasts
Data shows that the Precision Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -47.03% over the past 6 months, a 123.58% in annual growth rate that is considerably higher than the industry average of 16.40%. Year-over-year growth is forecast to reach 48.38% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 4.28M. 1 analysts are of the opinion that Precision Biosciences Inc’s revenue for the current quarter will be 10M. The company’s revenue for the corresponding quarters a year ago was 7.04M and 17.58M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -39.26%. The estimates for the next quarter sales put growth at -43.13%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.97%. The 2025 estimates are for Precision Biosciences Inc earnings to increase by 100.42%.
DTIL Dividends
Precision Biosciences Inc is expected to release its next quarterly earnings report in February.
Precision Biosciences Inc (NASDAQ:DTIL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.40% of Precision Biosciences Inc shares while 43.45% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 46.41%.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 174.93 shares estimated at $0.99 million under it, the former controlled 2.28% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.52% of the shares, roughly 39.95 shares worth around $0.23 million.
